Pharmaceutical Actions of Afatinib

  • Author:Ray Dean
  • Release on :2016-10-20

Afatinib is an oral drug and is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinase. Phase IIb / III randomized studies have shown that compared with placebo plus best supportive care, patients who received the best supportive regimen of alfentanil versus non-small-cell lung cancer who had previously failed a second-line chemotherapy and failed EGFR-TKI therapy, Survival, but significantly improved progression-free survival, improved ORR and 8-week disease control rate. In another study (LUX-LUNG2), the majority of patients (61%) with common EGFR mutations showed a significant reduction in tumor size, delayed tumor progression, and longer survival after treatment with alfatinib. These results confirmed that alfentanil is a promising target drug.


It is the second generation of highly efficient dual irreversible tyrosine kinase inhibitors. Erlotinib and gefitinib as a tyrosine kinase inhibitor, EGFR alone inhibition, BIBW2992 while inhibiting EGFR and HER-2 receptors. James St, Gay Medical College, London, UK, and other patients with solid tumors were studied in a phase I clinical study showed EGFR mutations in patients with NSCLC can get encouraging results, 20% of patients with persistent PR (2 women and 1 male), of which 2 showed deletion of EGFR exon 19, which was more common in women, non-smokers and adenocarcinoma patients.


Hubei Ocean Biotech Co., Ltd, a leading professional chemical industry enterprise with integrating production and trade for global valued customer with our superior quality and reliable cooperation. Should you have any interest in our APIs Pharma Products, welcome to take view at our site and be feel free to contact me.